Aberdeen Group plc Buys 44,685 Shares of LivaNova PLC $LIVN

Key Points

• Aberdeen Group plc increased its stake in LivaNova PLC by 19.3%, acquiring 44,685 shares, which brought its total holdings to 276,710 shares valued at approximately $10.87 million.
• LivaNova reported an earnings per share (EPS) of $1.05 for the quarter, surpassing analyst expectations of $0.84 and reflecting a 10.6% year-over-year revenue increase.
• Several analysts have upgraded LivaNova's stock rating, with a consensus target price of $59.29, indicating a generally positive outlook among analysts.

Aberdeen Group plc increased its holdings in LivaNova PLC (NASDAQ:LIVN - Free Report) by 19.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 276,710 shares of the company's stock after purchasing an additional 44,685 shares during the quarter. Aberdeen Group plc owned 0.51% of LivaNova worth $10,869,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Fox Run Management L.L.C. raised its holdings in shares of LivaNova by 35.3% in the 1st quarter. Fox Run Management L.L.C. now owns 26,838 shares of the company's stock worth $1,054,000 after purchasing an additional 6,995 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its holdings in shares of LivaNova by 415.4% during the first quarter. Caitong International Asset Management Co. Ltd now owns 1,469 shares of the company's stock valued at $58,000 after acquiring an additional 1,184 shares during the period. Russell Investments Group Ltd. raised its holdings in shares of LivaNova by 4,581.9% during the first quarter. Russell Investments Group Ltd. now owns 70,322 shares of the company's stock valued at $2,762,000 after acquiring an additional 68,820 shares during the period. Nuveen LLC acquired a new stake in shares of LivaNova during the first quarter valued at approximately $30,954,000. Finally, Invesco Ltd. raised its holdings in shares of LivaNova by 13.4% during the first quarter. Invesco Ltd. now owns 126,266 shares of the company's stock valued at $4,960,000 after acquiring an additional 14,892 shares during the period. 97.64% of the stock is currently owned by institutional investors.

LivaNova Stock Performance

LivaNova stock traded up $3.04 during mid-day trading on Friday, reaching $55.90. The company had a trading volume of 728,016 shares, compared to its average volume of 806,134. The company has a quick ratio of 1.09, a current ratio of 1.29 and a debt-to-equity ratio of 0.31. LivaNova PLC has a 52 week low of $32.48 and a 52 week high of $57.35. The company has a 50 day moving average of $46.42 and a 200-day moving average of $43.07. The firm has a market cap of $3.05 billion, a price-to-earnings ratio of -14.37 and a beta of 0.92.

LivaNova (NASDAQ:LIVN - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $1.05 earnings per share for the quarter, beating analysts' consensus estimates of $0.84 by $0.21. LivaNova had a negative net margin of 16.13% and a positive return on equity of 14.57%. The firm had revenue of $352.50 million during the quarter, compared to the consensus estimate of $332.20 million. During the same period in the prior year, the firm earned $0.93 EPS. The business's revenue was up 10.6% on a year-over-year basis. On average, sell-side analysts expect that LivaNova PLC will post 2.85 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Wolfe Research upgraded shares of LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 price target on the stock in a report on Tuesday, May 20th. Needham & Company LLC restated a "buy" rating and set a $64.00 price target on shares of LivaNova in a research note on Tuesday, May 13th. Wall Street Zen raised shares of LivaNova from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 9th. Robert W. Baird upped their price objective on shares of LivaNova from $55.00 to $61.00 and gave the stock an "outperform" rating in a report on Thursday, May 8th. Finally, Barclays upped their price objective on shares of LivaNova from $55.00 to $58.00 and gave the stock an "equal weight" rating in a report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat, LivaNova currently has an average rating of "Buy" and a consensus target price of $59.71.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.